Omthera Pharmaceuticals (OMTH) Files $75M IPO - InvestingChannel

Omthera Pharmaceuticals (OMTH) Files $75M IPO

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

Top NewsMost Read Highlighted

Get AlertsOMTH Hot Sheet

Omthera Pharmaceuticals (Nasdaq: OMTH) filed a registration with the U.S. Securities and Exchange Commission for an Initial Public Offering of its Common Stock. The proposed maximum offering price is $75 million. Omtera plans to list on the Nasdaq Global Market under the ticker “OMTH.”

The offering is being made through BofA Merrill Lynch, Barclays, Leerink Swann, Stifel, and Piper Jaffray.

Omthera is an emerging specialty pharmaceutical company focused on the development and commercialization of new therapies for abnormalities in blood lipids, referred to as dyslipidemia, and the treatment of cardiovascular disease.

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items – JOIN NOW